Skip to main content
SpringerLink
Log in

Cefaclor: Summary of clinical experience

Cefaclor: Zusammenfassung der klinischen Erfahrungen

  • Möglichkeiten Der Oralen Antibiotika-Therapie Mit Cefaclor
  • Published:
Infection Aims and scope Submit manuscript

Summary

Cefaclor, a new semisynthetic cephalosporin antibiotic for oral use, was studied by 62 clinical investigators in six countries in 1493 adult and paediatric patients. The pooled data reveal that satisfactory clinical responses were obtained in 80% of urinary tract infections, 87% of upper respiratory tract infections, 90% of cases of otitis media, 99% of lower respiratory tract infections, and 96% of skin and skin structure infections. Administration of this antibiotic was associated with a low incidence of adverse reactions including gastrointestinal (2.6%) and hypersensitivity (1.5%). Of particular clinical interest were the outstanding results obtained in the treatment of otitis media and lower respiratory tract infections.

Zusammenfassung

Cefaclor, ein neues semisynthetisches Cephalosporin-Antibiotikum zur oralen Anwendung, wurde von 62 klinischen Prüfern in sechs Ländern bei 1493 Erwachsenen und Kindern therapeutisch angewendet. Die zusammengefaßten Daten ergeben eine zufriedenstellende klinische Wirksamkeit bei 80% der Harnwegsinfektionen, 87% der Infektionen des oberen Respirationstraktes, 90% der Erkrankungen an Otitis media, 99% der Infektionen des unteren Respirationstraktes sowie 96% der Infektionen der Haut und Weichteile. Der Einsatz dieses Antibiotikums war mit einer niedrigen Rate an Nebenwirkungen, einschließlich gastrointestinaler (2,6%) und allergischer Natur (1,5%), verbunden. Von besonderer klinischer Bedeutung erscheinen die herausragenden Therapieerfolge bei Otitis media und bei Infektionen des unteren Respirationstraktes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Literature

  1. Bill, N. J., Washington, J. A. Comparison of in vitro activity of cephalexin, cephradine, and cefaclor. Antimicrob. Agents Chemother. 11 (1977) 470–474.

    Google Scholar 

  2. Jorgensen, J. H., Alexander, G. A. Comparative activities of selected beta-lactam antibiotics againstHaemophilus influenzae. Antimicrob. Agents Chemother. 13 (1978) 342–343.

    Google Scholar 

  3. Meyers, B. R., Hirschman, S. Z. Antimicrobial activity in vitro of cefaclor, a new oral cephalosporin. J. Clin. Pharmacol. 18 (1978) 85–90.

    Google Scholar 

  4. Neu, H. C., Fu, K. P. Cefaclor: in vitro spectrum of activity and beta-lactamase stability. Antimicrob. Agents Chemother. 13 (1978) 584–588.

    Google Scholar 

  5. Sanders, C. C. In vitro studies with cefaclor, a new oral cephalosporin. Antimicrob. Agents Chemother. 12 (1977) 490–497.

    Google Scholar 

  6. Santoro, J., Levison, M. E. In vitro activity of cefaclor, a new orally administered cephalosporin antibiotic. Antimicrob. Agents Chemother. 12 (1977) 442–443.

    Google Scholar 

  7. Shadomy, S., Wagner, G., Carver, M. In vitro activities of five oral cephalosporins against aerobic pathogenic bacteria. Antimicrob. Agents Chemother. 12 (1977) 609–613.

    Google Scholar 

  8. Sinai, R., Hammerberg, S., Marks, M. I., Pai, C. H. In vitro susceptibility ofHaemophilus influenzae to sulfamethoxazole-trimethoprim and cefaclor, cephalexin, and cephradine. Antimicrob. Agents Chemother. 13 (1978) 861–864.

    Google Scholar 

  9. Bloch, R., Szwed, J. J., Sloan, R. S., Luft, F. C. Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure. Antimicrob. Agents Chemother. 12 (1977) 730–732.

    Google Scholar 

  10. Korzeniowski, O. M., Scheld, W. M., Sande, M. A. Comparative pharmacology of cefaclor and cephalexin. Antimicrob. Agents Chemother. 12 (1977) 157–162.

    Google Scholar 

  11. Meyers, B. R., Hirschman, S. Z., Wormser, G., Gartenberg, G., Srulevitch, E. Pharmacologic studies with cefaclor, a new oral cephalosporin. J. Clin. Pharmacol. 18 (1978) 174–179.

    Google Scholar 

  12. Santoro, J., Agarwal, B. N., Martinelli, R., Wenger, N., Levison, M. E. Pharmacology of cefaclor in normal volunteers and patients with renal failure. Antimicrob. Agents Chemother. 13 (1978) 951–954.

    Google Scholar 

  13. Spyker, D. A., Thomas, B. L., Sande, M. A., Bolton, W. K. Pharmacokinetics of cefaclor and cephalexin: dosage nomograms for impaired renal function. Antimicrob. Agents Chemother. 14 (1978) 172–177.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lilly Research Laboratories, Division of Eli Lilly and Company, PO Box 618, 46206, Indianapolis, Indiana, USA

    R. B. Kammer & L. J. Short

Authors
  1. R. B. Kammer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. J. Short
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Der gleiche Vortrag wurde auf dem Symposium „Clinical Advances in Oral Antibiotic Therapy“, London, 21.–22. 9. 1978, gehalten und in „Postgraduate Medical Journal“ 55 Suppl. 4 (1979) 93–97 publiziert. Nachdruck mit freundlicher Genehmigung von The Fellowship of Postgraduate Medicine.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kammer, R.B., Short, L.J. Cefaclor: Summary of clinical experience. Infection 7 (Suppl 6), S631–S635 (1979). https://doi.org/10.1007/BF01659754

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01659754

Keywords

Search

Navigation